Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Reduction. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN107674026B details a high-yield CBS reduction route for ruxolitinib intermediates. This method ensures superior stereoselectivity and scalable supply chain reliability for global pharmaceutical manufacturers.
Novel asymmetric reduction route ensures high ee value and yield for Tegoprazan intermediate, offering significant supply chain stability and cost optimization for global pharmaceutical manufacturing partners.
Discover the novel synthetic method for Beraprost Sodium via selective hydroxyl protection. Enhance supply chain reliability and reduce API manufacturing costs.
Patent CN112852769A reveals a high-yield enzymatic route for (S)-1-(2-methoxy-3-bromophenyl) ethanol. Discover cost-effective, green manufacturing solutions for this critical API intermediate.
Patent CN1940079A details a novel baker's yeast reduction for synthesizing (2S,3S)-2-benzoyl aminomethyl-3-hydroxy-butyrate, a critical 4-AA precursor, offering mild conditions and high optical purity.
Patent CN112063531B reveals a novel Geotrichum candidum strain for Ticagrelor intermediate synthesis, offering high stereoselectivity and reduced manufacturing costs.
Patent CN102617503B details a novel Serine-based synthesis for high-purity S-3-Morpholinecarboxylic Acid, offering significant cost reduction and scalable manufacturing for pharmaceutical intermediates.
Patent CN1709864A discloses a high-yield asymmetric synthesis for Taxol side chains using low-cost glycolic acid and chiral tert-butyl sulfinamide, offering significant cost reduction in pharmaceutical manufacturing.
Patent CN112481226B details solvent-tolerant ADH mutants for scalable production of chiral alcohols, offering significant cost reduction and supply chain reliability for pharma intermediates.
Patent CN100376681C details a microbial asymmetric reduction method for (R)-mandelic acid using Saccharomyces cerevisiae, offering a green, cost-effective alternative to traditional chemical resolution for pharmaceutical manufacturing.
Patent CN114702475B reveals a copper-catalyzed route for single-configuration nicotine, offering high optical purity and significant cost reduction in pharmaceutical intermediate manufacturing.
Patent CN101260415A reveals high-efficiency biocatalytic route for chiral intermediates. Offers significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN101260415A reveals biocatalytic route for chiral intermediates. Offers supply chain stability and cost efficiency for pharmaceutical manufacturing.
Unprotected asymmetric process for nicotine production offers cost reduction and supply chain reliability for global agrochemical and pharmaceutical manufacturers seeking scalable solutions.
Patent CN107881202A enables high-purity levonorgestrel intermediate production. Biocatalysis ensures supply chain stability and cost efficiency for pharmaceutical manufacturers.
Novel biocatalytic route for (R)-1-(4-bromophenyl)-2,2,2-trifluoroethanol using Cyberlindnera saturnus. High ee, mild conditions, scalable pharma intermediate production.
Patent CN113462728A details a novel whole-cell biocatalytic route for high-purity chiral intermediates, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN112048538B reveals a high-yield biocatalytic route for Aprepitant intermediates using Cyberlindnera saturns, offering superior purity and cost efficiency.
Patent CN101547890A details a catalytic asymmetric synthesis of primary amines using spiroboronic esters, offering high enantioselectivity and cost-effective manufacturing for pharmaceutical intermediates.
Patent CN114686451A discloses amine dehydrogenase mutants for high-yield production. Offers cost reduction in pharma intermediate manufacturing with >99% ee.